| Item | Current | Prior | YoY % |
|---|---|---|---|
| Net Sales | ¥21.63B | ¥21.37B | +1.2% |
| Cost of Sales | ¥14.73B | ¥14.82B | -0.6% |
| Gross Profit | ¥6.90B | ¥6.55B | +5.3% |
| SG&A Expenses | ¥5.82B | ¥5.57B | +4.4% |
| Operating Income | ¥1.08B | ¥974M | +10.7% |
| Non-operating Income | ¥113M | ¥81M | +39.5% |
| Non-operating Expenses | ¥10M | ¥19M | -47.4% |
| Ordinary Income | ¥1.18B | ¥1.04B | +14.0% |
| Profit Before Tax | ¥1.29B | ¥1.23B | +5.1% |
| Income Tax Expense | ¥485M | ¥432M | +12.3% |
| Net Income | ¥803M | ¥794M | +1.1% |
| Net Income Attributable to Owners | ¥803M | ¥794M | +1.1% |
| Total Comprehensive Income | ¥1.07B | ¥690M | +55.4% |
| Interest Expense | ¥3M | ¥2M | +50.0% |
| Basic EPS | ¥79.87 | ¥74.46 | +7.3% |
| Diluted EPS | ¥79.66 | ¥74.25 | +7.3% |
| Dividend Per Share | ¥60.00 | ¥60.00 | +0.0% |
| Item | Current End | Prior End | Change |
|---|---|---|---|
| Current Assets | ¥17.79B | ¥18.23B | ¥-438M |
| Cash and Deposits | ¥9.05B | ¥9.42B | ¥-371M |
| Accounts Receivable | ¥5.79B | ¥6.21B | ¥-414M |
| Inventories | ¥1.03B | ¥785M | +¥244M |
| Non-current Assets | ¥18.56B | ¥17.79B | +¥771M |
| Item | Value |
|---|---|
| Net Profit Margin | 3.7% |
| Gross Profit Margin | 31.9% |
| Current Ratio | 229.7% |
| Quick Ratio | 216.4% |
| Debt-to-Equity Ratio | 0.44x |
| Interest Coverage Ratio | 359.33x |
| Effective Tax Rate | 37.7% |
| Item | YoY Change |
|---|---|
| Net Sales YoY Change | +1.2% |
| Operating Income YoY Change | +10.8% |
| Ordinary Income YoY Change | +14.1% |
| Net Income Attributable to Owners YoY Change | +1.1% |
| Total Comprehensive Income YoY Change | +55.3% |
| Item | Value |
|---|---|
| Shares Outstanding (incl. Treasury) | 10.88M shares |
| Treasury Stock | 898K shares |
| Average Shares Outstanding | 10.06M shares |
| Book Value Per Share | ¥2,531.52 |
| Item | Amount |
|---|---|
| Q2 Dividend | ¥60.00 |
| Year-End Dividend | ¥63.00 |
| Segment | Revenue | Operating Income |
|---|---|---|
| ClinicalTesting | ¥13.42B | ¥936M |
| DispensingPharmacy | ¥7.53B | ¥241M |
| ICT | ¥681M | ¥166M |
| Item | Forecast |
|---|---|
| Net Sales Forecast | ¥43.60B |
| Operating Income Forecast | ¥2.50B |
| Ordinary Income Forecast | ¥2.60B |
| Net Income Attributable to Owners Forecast | ¥1.95B |
| Basic EPS Forecast | ¥192.01 |
| Dividend Per Share Forecast | ¥62.50 |
| Property, Plant & Equipment | ¥11.54B | ¥11.27B | +¥270M |
| Intangible Assets | ¥564M | ¥543M | +¥21M |
| Investment Securities | ¥4.07B | ¥3.67B | +¥396M |
| Total Assets | ¥36.35B | ¥36.02B | +¥333M |
| Current Liabilities | ¥7.74B | ¥7.43B | +¥312M |
| Accounts Payable | ¥4.41B | ¥4.28B | +¥129M |
| Short-term Loans | ¥400M | ¥400M | ¥0 |
| Non-current Liabilities | ¥3.34B | ¥3.33B | +¥6M |
| Long-term Loans | ¥759M | ¥844M | ¥-85M |
| Total Liabilities | ¥11.08B | ¥10.77B | +¥318M |
| Total Equity | ¥25.27B | ¥25.25B | +¥16M |
| Capital Stock | ¥3.37B | ¥3.37B | ¥0 |
| Capital Surplus | ¥3.31B | ¥3.31B | ¥0 |
| Retained Earnings | ¥19.62B | ¥19.48B | +¥139M |
| Treasury Stock | ¥-1.98B | ¥-1.59B | ¥-390M |
| Owners' Equity | ¥25.20B | ¥25.18B | +¥19M |
| Working Capital | ¥10.05B | - | - |